GLSI
NASDAQ HealthcareGreenwich LifeSciences, Inc. - Common stock
Biotechnology
Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers in the United States. Its lead product candidate is GP2, a HER2/neu transmembrane peptide, which is in Phase III clinical trial to prevent breast cancer recurrences in patients. The company also develops FLAMINGO-01, which is in Phase IIb and 3 Phase I clinical trial designed to evaluate the safety and efficacy of GLSI-100 in HER2 positive breast cancer patients. Greenwich LifeSciences, Inc. was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. The company was incorporated in 2006 and is headquartered in Stafford, Texas.
๐ Market Data
| Price | $18.99 |
|---|---|
| Volume | 301,164 |
| Market Cap | 278.74M |
| Beta | 1.460 |
| RSI (14-Day) | 69.0 |
| 200-Day MA | $21.49 |
| 50-Day MA | $15.86 |
| 52-Week High | $34.10 |
| 52-Week Low | $7.78 |
| Forward P/E | -23.16 |
| Price / Book | 89.58 |
๐ฏ Investment Strategy Scores
GLSI scores across each investment strategy. Higher is better for that strategy's goals.
๐ Strategy Interpretation
Best fit: ๐ Over-Hyped (94/100) โ this strategy Overbought stocks (potential short candidates).
Lowest fit among scored strategies: ๐ Institutional Whale (7/100). No single score is a buy or sell signal โ use multiple lenses together. Learn how to read these scores โ
๐ Learn More
Indicators on this page
Educational articles
Find GLSI in your text
Paste any article, transcript, or post โ the tool will extract GLSI and every other hidden ticker.
Disclaimer: This data is for educational and entertainment purposes only and does not constitute financial advice. Market data may be delayed. Always do your own research before making investment decisions.
Data last updated: 2026-09-18.